Intravitreal Ranibizumab(유리체강내 라니비주맙)란 무엇입니까?
Intravitreal Ranibizumab 유리체강내 라니비주맙 - Purpose To evaluate the real-world effectiveness of intravitreal ranibizumab 0. [1] However, IVC showed non-inferior efficacy to intravitreal ranibizumab (IVR) according to low quality of evidence, and there was lack of trials comparing the priority of IVC to other anti-VEGF regimens. [2] The patient received 3 injections of intravitreal ranibizumab. [3] The use of intravitreal ranibizumab has been suggested as an alternative treatment or an alternative adjuvant before vitrectomy. [4] Medical records on 19 eyes of 19 patients whom intravitreal bevacizumab (IVB), intravitreal ranibizumab (IVR), and intravitreal aflibercept (IVA) injections were administered for CNV caused by PNV were enrolled into the study. [5] INTERVENTION Intravitreal ranibizumab 0. [6] In this prospective pilot study, we aimed to study SD-OCT changes in a high-frequent follow-up manner (weekly (month 0–6), biweekly (month 7–12)) throughout the first year, which consequently led to intravitreal ranibizumab being administered up to biweekly. [7] The rabbits were divided into 4 groups: control (n = 5), OGI group (n = 40), and intravitreal Ranibizumab and Conbercept (n = 15 each). [8] During the corticosteroids tapering, there was a recurrence of exudative retinal detachments, and megadoses of 1g of intravenous corticosteroids per day were reintroduced for 6 days until the complete resolution of the fluid of the exudative RD, and cyclosporine (100mg per day), subtenon triamcinolone (40mg/mL), and intravitreal ranibizumab once a month in the both eyes were added to the treatment, with a great control of choroidal inflammation that resulted in the remission of symptoms and signs. [9] Therapy with intravitreal ranibizumab was commenced. [10] Conclusion There is a significant difference between the preoperative and 1-month postoperative choroidal thickness using EDI-OCT after injection of intravitreal ranibizumab in DME. [11] Intravitreal ranibizumab (IVR) treatment was initiated because of distorted vision accompanied by the development of SHE and persistent subfoveal fluid accumulation, as documented by OCT during IVA treatment. [12] Her medical history was significant for nAMD of the right eye, and she had been receiving treatment with intravitreal ranibizumab [dosage not stated]. [13] Four monthly injections of intravitreal ranibizumab were administered, but PED persisted. [14] To assess the efficacy of a treat-and-extend strategy with intravitreal ranibizumab for radiation-related macular edema. [15] Aim: To investigate the anatomic outcomes of patients treated with intravitreal ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP). [16] Patients were treated with a fixed dosing regimen of intravitreal ranibizumab or aflibercept and followed up for 12 months. [17] Interventions: After the diagnosis of laser induced CNV, intravitreal ranibizumab (LUCENTIS, NOVARTIS) injection was performed. [18] Purpose: To compare the two-year visual and anatomical outcomes of combination therapy of photodynamic therapy (PDT) with intravitreal aflibercept (IVA) or intravitreal ranibizumab (IVR) for patients with polypoidal choroidal vasculopathy (PCV), and to investigate the clinical factors with final visual outcome and retreatment. [19] 62 years) were evaluated pre- and post-treatment of intravitreal ranibizumab with and without photodynamic therapy. [20] The aim of this retrospective study was to compare the clinical aspects of fluorescein angiographic characteristics in predominantly classic (PDC) and OCC subtypes of n-AMD treated with intravitreal ranibizumab. [21] PURPOSE To investigate the visual prognosis of patients with polypoidal choroidal vasculopathy (PCV) with a 5-year remission after an initial combination therapy involving photodynamic therapy (PDT) and intravitreal ranibizumab (IVR) or aflibercept injection (IVA). [22] METHODS Patients were randomized 3:2 to treatment with the PDS with ranibizumab 100 mg/mL with fixed 24-week refill-exchanges (PDS Q24W) or intravitreal ranibizumab 0. [23] A Pilot studies with intravitreal Ranibizumab have also shown decrease in mean retinal thickness and improved vision in patients with DME. [24] Intravitreal ranibizumab (0. [25] Methods: Electronic records of treatment-naïve eyes initiated on intravitreal ranibizumab between January and December 2009 were accessed. [26]목적 유리체강내 ranibizumab 0의 실제 효과를 평가합니다. [1] 그러나 IVC는 근거의 질이 낮아 유리체강내 라니비주맙(IVR)보다 비열등한 효능을 보였고, 다른 항-VEGF 요법과 IVC의 우선순위를 비교한 연구도 부족했다. [2] 환자는 유리체강내 라니비주맙을 3회 주사했습니다. [3] 유리체내 라니비주맙의 사용은 유리체절제술 전 대체 치료 또는 대체 보조제로 제안되었습니다. [4] PNV에 의한 CNV에 대해 유리체강내 베바시주맙(IVB), 유리체강내 라니비주맙(IVR) 및 유리체강내 애플리버셉트(IVA) 주사를 투여한 19명의 환자 19안의 의무기록을 연구에 등록하였다. [5] 간섭 유리체강내 라니비주맙 0. [6] 이 전향적 파일럿 연구에서 우리는 첫 1년 동안 높은 빈도의 추적 관찰 방식(매주(0-6개월), 격주(7-12개월))으로 SD-OCT 변화를 연구하는 것을 목표로 했으며 결과적으로 유리체내 라니비주맙은 최대 격주로 투여된다. [7] 토끼는 대조군(n = 5), OGI 그룹(n = 40), 유리체강내 Ranibizumab 및 Conbercept(각각 n = 15)의 4개 그룹으로 나누었습니다. [8] 코르티코스테로이드 테이퍼링 동안 삼출성 망막박리가 재발하여 삼출성 RD의 체액이 완전히 소실될 때까지 6일 동안 1일 1g의 정맥내 코르티코스테로이드 메가도스 및 사이클로스포린(1일 100mg), 테논하 트리암시놀론을 투여하였다. (40mg/mL) 및 두 눈에 한 달에 한 번 유리체강내 라니비주맙을 치료에 추가하여 맥락막 염증을 크게 제어하여 증상과 징후를 완화시켰습니다. [9] 유리체강내 라니비주맙 요법이 시작되었습니다. [10] 결론 DME에서 유리체강내 라니비주맙 주사 후 EDI-OCT를 사용한 수술 전과 수술 후 1개월 맥락막 두께 사이에는 유의한 차이가 있었다. [11] 유리체강내 라니비주맙(IVR) 치료는 IVA 치료 중 OCT에 의해 문서화된 바와 같이 SHE의 발달 및 지속적인 중심와하액 축적을 수반하는 왜곡된 시력 때문에 시작되었습니다. [12] 그녀의 병력은 오른쪽 눈의 nAMD에 대해 유의미했으며 유리체강내 라니비주맙[복용량은 명시되지 않음]으로 치료를 받고 있었습니다. [13] 유리체강내 라니비주맙을 4개월에 걸쳐 주사했지만 PED는 지속되었습니다. [14] 방사선 관련 황반 부종에 대해 유리체강내 라니비주맙을 사용한 치료 및 연장 전략의 효능을 평가합니다. [15] 목적: 제1형 치료에서 유리체강내 라니비주맙으로 치료받은 환자의 해부학적 결과 조사 미숙아 망막병증(ROP). [16] 환자는 유리체강내 라니비주맙 또는 애플리버셉트의 고정 용량 요법으로 치료를 받았고 12개월 동안 추적 관찰했습니다. [17] 중재: 레이저 유발 CNV 진단 후 유리체강내 라니비주맙(LUCENTIS, NOVARTIS) 주사를 시행하였다. [18] 목적: 폴립형 맥락막 혈관병증(PCV) 환자에서 PDT와 유리체강내 애플리버셉트(IVA) 또는 유리체강내 라니비주맙(IVR) 병용 요법의 2년 시각 및 해부학적 결과를 비교하고 임상적 요인을 알아보고자 하였다. 최종 시각적 결과 및 후퇴. [19] 62세) 광역학 요법을 포함하거나 포함하지 않는 유리체강내 라니비주맙의 치료 전후를 평가했습니다. [20] 이 후향적 연구의 목적은 유리체강내 라니비주맙으로 치료된 n-AMD의 우세하게 클래식(PDC) 및 OCC 아형에서 형광 혈관 조영 특성의 임상 측면을 비교하는 것이었습니다. [21] 목적 광역동 요법(PDT)과 유리체강내 라니비주맙(IVR) 또는 애플리버셉트 주사(IVA)를 포함하는 초기 병용 요법 후 5년 관해가 있는 폴립형 맥락막 혈관병증(PCV) 환자의 시각적 예후를 조사하기 위해. [22] 행동 양식 환자들은 라니비주맙 100mg/mL와 고정 24주 재충전-교환(PDS Q24W) 또는 유리체강내 라니비주맙 0을 사용한 PDS 치료에 3:2로 무작위 배정되었습니다. [23] 유리체강내 라니비주맙을 사용한 파일럿 연구에서도 DME 환자의 평균 망막 두께가 감소하고 시력이 개선된 것으로 나타났습니다. [24] 유리체강내 라니비주맙(0. [25] 방법: 2009년 1월에서 12월 사이에 유리체강내 라니비주맙에서 시작된 치료 경험이 없는 눈의 전자 기록에 액세스했습니다. [26]
diabetic macular edema 당뇨병성 황반부종
Given the growing evidence of the role of choroidal dysfunction, our purpose was to assess choroidal vascular changes with intravitreal ranibizumab (RBZ) treatment in diabetic macular edema (DME). [1] The study aims to investigate changes in the aqueous humor levels of 8 growth factors and inflammatory mediators after intravitreal ranibizumab injection (IRI) and the relationship between these substances and functional-morphological parameters in patients with diabetic macular edema (DME). [2] Furthermore, in two clinical trials, R-(+)-lipoic acid (RLA) in combination with hyperbaric oxygenation therapy (HBOT) for treatment of chronic wound healing in DM patients, as well as supplementation with DHA plus antioxidants along with intravitreal ranibizumab were investigated for its effects on diabetic macular edema. [3] Purpose This retrospective study aimed to compare the efficacy of intravitreal ranibizumab (IVR) and intravitreal dexamethasone implant (IDI) for pseudophakic vitrectomized eyes with diabetic macular edema (DME) in a single institution. [4] PURPOSE: The purpose of this study is to compare the efficacy of intravitreal ranibizumab (IVR) alone and concurrent IVR with posterior subtenon triamcinolone acetonide (PSTA) injection for patients with diabetic macular edema (DME) refractory to IVR monotherapy. [5] Aim: The aim of this study is to compare the effectiveness of intravitreal Ranibizumab and Triamcinolone acetonide in management of diabetic macular edema with epiretinal membrane in pseudophakic patients. [6] To investigate changes in macular and panretinal neuroretinal functions by electroretinographic examinations in eyes with diabetic macular edema (DME) treated with intravitreal ranibizumab. [7] Purpose To assess injection patterns and vision outcomes in patients receiving intravitreal ranibizumab injections for diabetic macular edema in a real-world clinical setting. [8] ABSTRACT Purpose To evaluate and compare the effect of intravitreal ranibizumab and aflibercept on the treatment of diabetic macular edema in previously vitrectomized eyes. [9] PURPOSE To evaluate and compare the effects of intravitreal ranibizumab and aflibercept treatment on retinal vessel diameters in patients with diabetic macular edema (DME). [10] Introduction: To evaluate the effectiveness and safety of intravitreal dexamethasone (DEX) implants in refractory diabetic macular edema (DME) treated by intravitreal ranibizumab. [11] PurposeTo evaluate and compare the functional and anatomical outcomes of intravitreal ranibizumab (IVR) and aflibercept (IVA) treatments in patients with diabetic macular edema (DME). [12] The treatment-naïve diabetic macular edema patients who had diabetic macular edema associated with subfoveal retinal detachment and underwent intravitreal aflibercept or intravitreal ranibizumab treatment were included. [13] The decrease in macular thickness observed at 24 months was maintained at Month 36 in patients with diabetic macular edema treated with a combination of intravitreal ranibizumab and oral supplementation with high-dose docosahexaenoic acid and antioxidants. [14] Background: to monitor and compare the effect of intravitreal ranibizumab injection alone or with sub-tenon triamcinolone acetonide injection on patients with diabetic macular edema. [15] Estudo comparativo entre o tratamento intravítreo com ranibizumabe e triancinolona do edema macular diabético quanto às alterações na tomografia de coerência óptica e na acuidade visual Comparative study between intravitreal ranibizumab and triamcinolone treatment of diabetic macular edema as regard to optical coherence tomography changes and visual acuity. [16]맥락막 기능 장애의 역할에 대한 증가하는 증거를 감안할 때, 우리의 목적은 당뇨병성 황반 부종(DME)에서 유리체강내 라니비주맙(RBZ) 치료로 맥락막 혈관 변화를 평가하는 것이었습니다. [1] 이 연구는 당뇨병성 황반부종(DME) 환자에서 유리체강내 라니비주맙 주사(IRI) 후 8가지 성장인자와 염증 매개체의 방수 수치 변화와 이들 물질과 기능적-형태학적 매개변수 사이의 관계를 조사하는 것을 목적으로 합니다. [2] nan [3] nan [4] nan [5] nan [6] nan [7] 목적 실제 임상 환경에서 당뇨병성 황반 부종에 대해 유리체강내 라니비주맙 주사를 받는 환자의 주사 패턴 및 시력 결과를 평가합니다. [8] nan [9] nan [10] nan [11] nan [12] nan [13] nan [14] nan [15] nan [16]
neovascular age related 신생혈관 연령 관련
ABSTRACT Purpose: To investigate the effects of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) on systemic inflammatory and cardiovascular biomarkers in treatment-naive patients with neovascular age-related macular degeneration (nAMD) Methods: This study included 24 eyes of 24 patients treated with 0. [1] METHODS This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after ≥6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. [2] Purpose To compare functional and anatomic outcome of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) treatments in neovascular age related macular degeneration (nAMD) by using the treat an extend (TE) protocol. [3] Purpose: The aim of this study was to evaluate the safety, efficacy, and morphological response of intravitreal ranibizumab biosimilar (Razumab) in neovascular age-related macular degeneration (n-AMD) up to 12 weeks. [4] Design, Setting, and Participants This economic evaluation predominantly used data from the Center for Value-Based Medicine database to perform preference-based comparative effectiveness and cost-utility analyses for cataract surgery and intravitreal ranibizumab therapy for neovascular age-related macular degeneration (NVAMD) using vision utilities acquired from patients with ophthalmic disease (ophthalmic patient utilities) and from surrogate individuals (nonophthalmic patient vision utilities) with and without integrating systemic comorbidity utility limits on vision utility gain. [5] IntroductionThis study sought to determine the cost-effectiveness of intravitreal ranibizumab compared with best supportive care (BSC; considered to be no active treatment) for the treatment of visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular degeneration (nAMD) and pathologic myopia (PM) in a UK setting. [6] ABSTRACT Purpose: To study (i) the long-term effects of intravitreal ranibizumab treatment on changes in submacular choroidal thickness and (ii) the relationship between any resulting changes in choroidal thickness and visual outcomes following such treatment in patients with neovascular age-related macular degeneration (n-AMD). [7]초록 목적: 치료 경험이 없는 신생혈관성 연령 관련 황반변성(nAMD) 환자의 전신 염증 및 심혈관 바이오마커에 대한 유리체강내 라니비주맙(IVR) 및 유리체내 애플리버셉트(IVA)의 효과를 조사하기 위해 방법: 24명의 환자 24안을 대상으로 하였다. 0으로 처리합니다. [1] 행동 양식 이 후향적 연구는 이전에 4~8주 간격으로 라니비주맙을 6회 이상 유리체강내 주사한 후 애플리버셉트로 전환한 신생혈관 연령 관련 황반변성 환자를 조사했습니다. [2] nan [3] 목적: 이 연구의 목적은 최대 12주까지의 신생혈관 연령 관련 황반변성(n-AMD)에서 유리체강내 라니비주맙 바이오시밀러(Razumab)의 안전성, 유효성 및 형태학적 반응을 평가하는 것이었습니다. [4] 디자인, 설정 및 참가자 이 경제성 평가는 주로 가치 기반 의학 센터 데이터베이스의 데이터를 사용하여 환자로부터 얻은 시력 유틸리티를 사용하여 신생혈관성 연령 관련 황반변성(NVAMD)에 대한 백내장 수술 및 유리체강내 라니비주맙 치료에 대한 선호도 기반 비교 효과 및 비용 활용 분석을 수행했습니다. 안과 질환이 있는 경우(안과 환자 유틸리티) 및 대리 개인(비안과 환자의 시력 유틸리티)에서 전신 동반이환 유틸리티를 통합하거나 통합하지 않은 경우 시력 효용 이득에 대한 제한이 있습니다. [5] nan [6] nan [7]
branch retinal vein 가지 망막 정맥
Purpose To report a case of branch retinal vein occlusion (BRVO) in which rapid formation of macular pucker was observed after an intravitreal ranibizumab (IVR) injection. [1] To evaluate the effects of intravitreal ranibizumab injection (IVR) on metamorphopsia in patients with branch retinal vein occlusion (BRVO), and to assess the relationship between metamorphopsia and inner retinal microstructure and other factors. [2] To quantify aniseikonia following intravitreal ranibizumab (IVR) in patients with branch retinal vein occlusion (BRVO) and assess the relationship between aniseikonia and retinal microstructure. [3] AIM To identify factors contributing to visual improvement after treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO), and to assess the interaction between laser therapy and intravitreal ranibizumab (IVR). [4] ABSTRACT Purpose: To report 24-month results after one intravitreal ranibizumab (IVR) injection followed by pro re nata (PRN) dosing for macular edema (ME) after branch retinal vein occlusion (BRVO). [5] We investigated the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections for macular edema (ME) due to branch retinal vein occlusion (BRVO). [6] PURPOSE To evaluate stereopsis before and after intravitreal ranibizumab (IVR) injections in patients with branch retinal vein occlusion (BRVO) and investigate the relationship between stereopsis and retinal microstructure. [7]목적 유리체강내 라니비주맙(IVR) 주사 후 황반주름의 급격한 형성이 관찰된 망막분지정맥폐쇄(BRVO) 1예를 보고하고자 한다. [1] 망막 분지 정맥 폐색(BRVO) 환자에서 유리체강내 라니비주맙 주사(IVR)가 변태에 미치는 영향을 평가하고 변태와 망막 내부 미세구조 및 기타 요인 간의 관계를 평가합니다. [2] nan [3] nan [4] nan [5] nan [6] nan [7]
vision related quality 비전 관련 품질
The study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. [1] Purpose: To assess the vision-related quality of life (VR-QOL) following intravitreal ranibizumab (IVR) for branch retinal vein occlusion (BRVO) and to evaluate subscale items of the VR-QOL. [2] Aims: To investigate the changes in vision-related quality of life after a loading dose of three consecutive intravitreal ranibizumab (IVR) injections in patients with unilateral diabetic macular edema (DME). [3] The aim of this study was to evaluate the vision-related quality of life (VR-QOL) before and after intravitreal ranibizumab injections (IVR) for central retinal vein occlusion (CRVO) and investigate subscale items of VR-QOL in detail. [4] The study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. [5] Purpose: To investigate vision-related quality of life in patients referred to the Italian Retina Services for intravitreal ranibizumab treatment for choroidal neovascularization due to pathologic myopia. [6]이 연구는 유리체강내 라니비주맙 주사(IVR) 후 중심 망막 정맥 폐쇄(CRVO) 환자의 입체시 및 시력 관련 삶의 질(VR-QOL) 변화를 평가하고 입체시와 VR-QOL 간의 관계를 조사하는 것을 목표로 했습니다. [1] 목적: 망막 분지 정맥 폐쇄(BRVO)에 대한 유리체내 라니비주맙(IVR) 후 시력 관련 삶의 질(VR-QOL)을 평가하고 VR-QOL의 하위 척도 항목을 평가합니다. [2] nan [3] nan [4] nan [5] nan [6]
optical coherence tomography 광간섭 단층촬영
PURPOSE To determine the prognostic characteristics of optical coherence tomography (OCT) parameters by evaluating diabetic macular edema (DME) patients with early dexamethasone (DEX) shift after three doses of intravitreal ranibizumab (RNB) injection. [1] The purpose was to demonstrate the diagnostic and therapeutic feasibility of swept source-optical coherence tomography angiography (SS-OCTA) by picturing neovascular changes secondary to a rare white dot syndrome following long-term intravitreal ranibizumab (IVR). [2] The medical records, including of ophthalmologic examinations and optical coherence tomography (OCT) images, of 106 patients with DME treated with either intravitreal ranibizumab or aflibercept were reviewed. [3] Purpose: To compare the effect of intravitreal ranibizumab (IVR) or intravitreal dexamethasone implants (IVD) on regression of hyperreflective dots (HRDs) on optical coherence tomography (OCT) B-scan in patients with branch retinal vein occlusion (BRVO). [4] Objective: To identify features in enhanced depth imaging spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), and fundus auto fluorescence (FAF) of patients with neovascular age-related macular degeneration (nAMD), as image markers of poor response to intravitreal Ranibizumab therapy. [5]목적 유리체강내 라니비주맙(RNB) 주사 3회 투여 후 조기 덱사메타손(DEX) 변화가 있는 당뇨병성 황반 부종(DME) 환자를 평가하여 광간섭 단층촬영(OCT) 매개변수의 예후 특성을 결정합니다. [1] 목적은 장기 유리체강내 라니비주맙(IVR) 후 희귀 백색점 증후군에 이차적으로 발생하는 신생혈관 변화를 그림으로써 스위프 소스-광간섭 단층촬영 혈관조영술(SS-OCTA)의 진단 및 치료 가능성을 입증하는 것이었습니다. [2] 유리체강내 라니비주맙 또는 애플리버셉트로 치료받은 DME 환자 106명의 안과 검사 및 광간섭 단층촬영(OCT) 영상을 포함한 의료 기록을 검토했습니다. [3] nan [4] nan [5]
aggressive posterior retinopathy 공격성 후방망막병증
Purpose: The aim of this study was to report the treatment outcomes of early and deferred laser in infants of aggressive posterior retinopathy of prematurity (APROP) after initial treatment with intravitreal Ranibizumab (IVR). [1] Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab. [2] Published in this issue of Indian Journal of Ophthalmology is a retrospective cohort of 24 infants with posterior zone 1 or ‘zone half’ aggressive posterior retinopathy of prematurity (APROP) who underwent intravitreal ranibizumab followed by laser photoablation between days 24 and 34 after the injection. [3] OBJECTIVES To report the results of intravitreal ranibizumab injection as primary therapy in aggressive posterior retinopathy of prematurity, the process of the disease, and the additive treatments performed. [4]목적: 이 연구의 목적은 유리체강내 라니비주맙(IVR) 초기 치료 후 미숙아 공격성 후방망막병증(APROP) 영아에서 조기 및 지연 레이저의 치료 결과를 보고하는 것입니다. [1] 유리체강내 라니비주맙으로 초기 치료 후 미숙아의 공격적 후방망막병증에 대한 결과 및 예후 인자. [2] 인도 안과 저널(Indian Journal of Ophthalmology) 이번 호에 유리체강내 라니비주맙을 시행한 후 주사 후 24일에서 34일 사이에 레이저 광절제술을 받은 미숙아 후방 영역 1 또는 '영역 절반' 공격성 후방 망막병증(APROP)이 있는 24명의 후향적 코호트가 게시되었습니다. [3] nan [4]
myopic choroidal neovascularization
Purpose To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV). [1] PURPOSE To determine the 5-year outcome of intravitreal ranibizumab (IVR) for myopic choroidal neovascularization (CNV). [2] Purpose To analyze the long-term outcomes and safety of intravitreal ranibizumab injections in myopic choroidal neovascularization (CNV). [3]age related macular 연령 관련 황반
Introduction To analyze the morphological and functional features of choroidal neovascularizations (CNVs) in eyes affected by pattern dystrophies (PD), evaluating their long-term response to intravitreal ranibizumab, and comparing them with CNVs in age-related macular degeneration (AMD). [1] ABSTRACT SIGNIFICANCE Acute retinal necrosis (ARN) may occur after intravitreal ranibizumab (IVR) treatment for patients with exudative age-related macular degeneration (AMD). [2] The purpose is to evaluate the effects of multiple intravitreal ranibizumab (IVR) and aflibercept (IVA) injections on peripapillary retinal nerve fiber layer (RNFL) thickness in patients with exudative age-related macular degeneration (AMD). [3]서론 패턴 이영양증(PD)의 영향을 받는 눈에서 맥락막 신생혈관(CNV)의 형태학적 및 기능적 특징을 분석하고, 유리체강내 라니비주맙에 대한 장기 반응을 평가하고, 연령 관련 황반변성(AMD)에서 CNV와 비교합니다. [1] 추상적인 의미 급성 망막 괴사(ARN)는 삼출성 연령 관련 황반 변성(AMD) 환자에 대한 유리체강내 라니비주맙(IVR) 치료 후에 발생할 수 있습니다. [2] nan [3]
best corrected visual 가장 잘 보정된 비주얼
Conclusion: Intravitreal Ranibizumab is more effective in patients presented early than late in improving best corrected visual acuity ( BCVA) and decreasing CMT. [1] After intravitreal ranibizumab injection, central macular thickness (CMT) and best-corrected visual acuity (BCVA) were measured before, 1, 2, 3, and 6 months later. [2]결론: 유리체강내 라니비주맙은 최고교정시력(BCVA)을 개선하고 CMT를 감소시키는 데 늦게보다 일찍 내원한 환자에서 더 효과적이었습니다. [1] nan [2]
central retinal vein 중심 망막 정맥
We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. [1] To identify anatomic endpoints altered by intravitreal ranibizumab in central retinal vein occlusion (CRVO) to determine any potential underlying disease modification that occurs with anti-vascular endothelial growth factor (anti-VEGF) therapy beyond best-corrected visual acuity and central optical coherence tomography outcomes. [2]중심 망막 정맥 폐쇄로 인한 황반 부종의 치료를 위한 유리체강내 라니비주맙(루센티스), 애플리버셉트(아일리아) 및 베바시주맙(아바스틴)의 비용 효율성을 평가하는 것이 목적이었습니다. [1] 중심 망막 정맥 폐색(CRVO)에서 유리체강내 라니비주맙에 의해 변경된 해부학적 종말점을 확인하여 항혈관 내피 성장 인자(항-VEGF) 요법으로 발생하는 잠재적인 기저 질환 변형을 확인하여 최적으로 교정된 시력 및 중심 광간섭 단층촬영 결과를 넘어선 결과를 확인합니다. . [2]
Received Intravitreal Ranibizumab 유리체강내 라니비주맙 투여
3%) received intravitreal ranibizumab injections (IVR); and 2 infants (4 eyes, 0. [1] Methods: A total of 40 patients recruited to this investigator-initiated trial received intravitreal ranibizumab monthly for 3 months. [2] Initially, he had received intravitreal ranibizumab and aflibercept for AMD along with photodynamic therapy for 8 years; however, the choroidal neovascularisation (CNV) had become refractory to these therapies. [3] Purpose: To evaluate angiographic findings in neonates up to 150 weeks postmenstrual age who received intravitreal ranibizumab for primary treatment of Type 1 retinopathy of prematurity. [4] The participants were patients with treatment-naïve neovascular AMD who received intravitreal ranibizumab (IVR) monthly injection at least three times as the loading phase, followed by further injections as needed (pro re nata (PRN)) and follow-up assessments for 5 years. [5]3%) 유리체강내 라니비주맙 주사(IVR)를 받았고; 및 유아 2명(4안, 0. [1] 방법: 이 조사자 개시 시험에 모집된 총 40명의 환자가 3개월 동안 매월 유리체강내 라니비주맙을 투여받았다. [2] nan [3] nan [4] nan [5]
Monthly Intravitreal Ranibizumab
Eligible patients were randomized to (1) daily oral ASP8232 40 mg monotherapy; (2) combination therapy of daily oral ASP8232 40 mg and monthly intravitreal ranibizumab 0. [1] Patients, meeting strict eligibility criteria for one of two subgroups (primary treatment failure or suboptimal treatment response), received 3 monthly intravitreal ranibizumab injections (0. [2] Methods and analysis We retrospectively analysed the phase III RIDE (NCT00473382) and RISE (NCT00473330) trials, in which 759 patients with DME were randomised to monthly intravitreal ranibizumab 0. [3] Every BRVO-affected eye was treated with monthly intravitreal ranibizumab injection. [4]Either Intravitreal Ranibizumab 유리체강내 라니비주맙
Patients and Methods A retrospective cohort analysis of treatment naive patients with myopic CNV who received treatment with either intravitreal ranibizumab or aflibercept over a 12-year period from September 2007 to May 2020 was performed. [1] The medical records, including of ophthalmologic examinations and optical coherence tomography (OCT) images, of 106 patients with DME treated with either intravitreal ranibizumab or aflibercept were reviewed. [2] Methods Participants in this study were 36 patients with DME, treated with either intravitreal ranibizumab (n = 16) or aflibercept (n = 20). [3] We retrospectively reviewed the medical records of 126 eyes with nAMD treated with either intravitreal ranibizumab or aflibercept, including ophthalmologic examinations and spectral-domain OCT at baseline and months 3, 6, and 12 after first injection. [4]환자 및 방법 2007년 9월부터 2020년 5월까지 12년 동안 유리체강내 라니비주맙 또는 애플리버셉트로 치료를 받은 근시 CNV의 치료 경험이 없는 환자의 후향적 코호트 분석을 수행했습니다. [1] 유리체강내 라니비주맙 또는 애플리버셉트로 치료받은 DME 환자 106명의 안과 검사 및 광간섭 단층촬영(OCT) 영상을 포함한 의료 기록을 검토했습니다. [2] nan [3] nan [4]
Following Intravitreal Ranibizumab 유리체강내 라니비주맙 투여 후
The study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. [1] Purpose: To assess the vision-related quality of life (VR-QOL) following intravitreal ranibizumab (IVR) for branch retinal vein occlusion (BRVO) and to evaluate subscale items of the VR-QOL. [2] To quantify aniseikonia following intravitreal ranibizumab (IVR) in patients with branch retinal vein occlusion (BRVO) and assess the relationship between aniseikonia and retinal microstructure. [3] The study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. [4]이 연구는 유리체강내 라니비주맙 주사(IVR) 후 중심 망막 정맥 폐쇄(CRVO) 환자의 입체시 및 시력 관련 삶의 질(VR-QOL) 변화를 평가하고 입체시와 VR-QOL 간의 관계를 조사하는 것을 목표로 했습니다. [1] 목적: 망막 분지 정맥 폐쇄(BRVO)에 대한 유리체내 라니비주맙(IVR) 후 시력 관련 삶의 질(VR-QOL)을 평가하고 VR-QOL의 하위 척도 항목을 평가합니다. [2] nan [3] nan [4]
Receiving Intravitreal Ranibizumab 유리체강내 라니비주맙 투여
Methods: A retrospective chart review of 796 eyes of 574 patients receiving intravitreal ranibizumab (0. [1] Purpose To assess injection patterns and vision outcomes in patients receiving intravitreal ranibizumab injections for diabetic macular edema in a real-world clinical setting. [2] METHODS Between July 2013 and January 2015, 119 eyes receiving intravitreal ranibizumab for DME were retrospectively recruited. [3]방법: 유리체강내 라니비주맙을 투여받은 574명의 환자 796안을 대상으로 한 후향적 차트 검토(0. [1] 목적 실제 임상 환경에서 당뇨병성 황반 부종에 대해 유리체강내 라니비주맙 주사를 받는 환자의 주사 패턴 및 시력 결과를 평가합니다. [2] nan [3]
Underwent Intravitreal Ranibizumab 유리체강내 라니비주맙 시술
All eyes underwent intravitreal ranibizumab injection combined with ablation therapy, 14 (87. [1] Published in this issue of Indian Journal of Ophthalmology is a retrospective cohort of 24 infants with posterior zone 1 or ‘zone half’ aggressive posterior retinopathy of prematurity (APROP) who underwent intravitreal ranibizumab followed by laser photoablation between days 24 and 34 after the injection. [2] METHODS The records of the nAMD patients who underwent intravitreal ranibizumab or aflibercept treatment, received the 3 monthly loading doses, and completed a follow-up period of 12 months were included retrospectively. [3]모든 눈은 절제 요법과 결합된 유리체강내 라니비주맙 주사를 받았습니다. 14(87. [1] 인도 안과 저널(Indian Journal of Ophthalmology) 이번 호에 유리체강내 라니비주맙을 시행한 후 주사 후 24일에서 34일 사이에 레이저 광절제술을 받은 미숙아 후방 영역 1 또는 '영역 절반' 공격성 후방 망막병증(APROP)이 있는 24명의 후향적 코호트가 게시되었습니다. [2] nan [3]
Single Intravitreal Ranibizumab
She was treated with single intravitreal ranibizumab injection. [1] BackgroundTo evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion(RVO), and to investigate the short term response after a single intravitreal ranibizumab (IVR) injection. [2]그녀는 단일 유리체내 라니비주맙 주사로 치료를 받았습니다. [1] nan [2]
3 Intravitreal Ranibizumab 3 유리체강내 라니비주맙
After 3 intravitreal ranibizumab injections, his neovascularization regressed on optic coherence tomography-angiography and his visual acuity improved. [1] Prior to the current presentation, she had been receiving 3 intravitreal ranibizumab injections and 9 intravitreal aflibercept injections. [2]유리체강내 라니비주맙 주사 3회 후 광간섭단층촬영-혈관조영술에서 신생혈관이 퇴행하고 시력이 호전되었다. [1] 현재 발표 전에 그녀는 유리체강내 라니비주맙 주사 3회와 유리체강내 애플리버셉트 주사 9회를 받았습니다. [2]
intravitreal ranibizumab injection 유리체강내 라니비주맙 주사
After 3 intravitreal ranibizumab injections, his neovascularization regressed on optic coherence tomography-angiography and his visual acuity improved. [1] This case report depicts how a case of the subretinal neovascular membrane was managed with intravitreal ranibizumab injections. [2] Six eyes had previous diode laser photocoagulation, and one eye had received an intravitreal ranibizumab injection. [3] The study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. [4] The study aims to investigate changes in the aqueous humor levels of 8 growth factors and inflammatory mediators after intravitreal ranibizumab injection (IRI) and the relationship between these substances and functional-morphological parameters in patients with diabetic macular edema (DME). [5] Aim: To assess the role of vitrectomy with internal limiting membrane (ILM) peeling with intravitreal ranibizumab injection for patients with CRVO with combined epiretinal membrane (ERM). [6] Prior to the current presentation, she had been receiving 3 intravitreal ranibizumab injections and 9 intravitreal aflibercept injections. [7] To evaluate the effects of intravitreal ranibizumab injection (IVR) on metamorphopsia in patients with branch retinal vein occlusion (BRVO), and to assess the relationship between metamorphopsia and inner retinal microstructure and other factors. [8] She was treated with single intravitreal ranibizumab injection. [9] METHODS This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after ≥6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. [10] Purpose To assess injection patterns and vision outcomes in patients receiving intravitreal ranibizumab injections for diabetic macular edema in a real-world clinical setting. [11] The aim of this study was to evaluate the vision-related quality of life (VR-QOL) before and after intravitreal ranibizumab injections (IVR) for central retinal vein occlusion (CRVO) and investigate subscale items of VR-QOL in detail. [12] The study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. [13] Thirty-three eyes were treated with intravitreal aflibercept injections, and 21 eyes were treated with intravitreal ranibizumab injections. [14] Intravitreal ranibizumab injections were administered three times at four-week intervals. [15] All eyes underwent intravitreal ranibizumab injection combined with ablation therapy, 14 (87. [16] 3%) received intravitreal ranibizumab injections (IVR); and 2 infants (4 eyes, 0. [17] Intravitreal aflibercept was administered as rescue therapy after persistent retinal neovascularization following retinal photocoagulation, periocular triamcinolone, and intravitreal ranibizumab injection. [18] Anatomic improvements after intravitreal ranibizumab injection in both eyes were significant but were temporary. [19] Antiglaucoma medications, intravitreal ranibizumab injection and local radiotherapy were ineffective in reducing her intraocular pressure (IOP) and ocular pain. [20] The man had a history of hypertension, aortic valve replacement, photodynamic therapy, and received 2 intravitreal ranibizumab injections and 54 intravitreal aflibercept injections since 2012 for typical AMD OD. [21] After intravitreal ranibizumab injection, central macular thickness (CMT) and best-corrected visual acuity (BCVA) were measured before, 1, 2, 3, and 6 months later. [22] All patients underwent vitrectomy without SRH management, followed by intravitreal ranibizumab injections and/or photodynamic therapy (PDT) as needed. [23] Objective To observe the efficacy of intravitreal ranibizumab injection with panretinal photocoagulation for the treatment of neovascular glaucoma. [24] BackgroundTo report the first case of human herpesvirus-6 (HHV-6) corneal endotheliitis that developed after intravitreal ranibizumab injections. [25] Following an intravitreal ranibizumab injection, he reported loss of vision 2 days later. [26] Purpose To analyze the long-term outcomes and safety of intravitreal ranibizumab injections in myopic choroidal neovascularization (CNV). [27] OBJECTIVES To report the results of intravitreal ranibizumab injection as primary therapy in aggressive posterior retinopathy of prematurity, the process of the disease, and the additive treatments performed. [28] Patients, meeting strict eligibility criteria for one of two subgroups (primary treatment failure or suboptimal treatment response), received 3 monthly intravitreal ranibizumab injections (0. [29] Background: to monitor and compare the effect of intravitreal ranibizumab injection alone or with sub-tenon triamcinolone acetonide injection on patients with diabetic macular edema. [30] We investigated the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections for macular edema (ME) due to branch retinal vein occlusion (BRVO). [31] Purpose: comparing the efficacy and safety of intravitreal ranibizumab injection, corticosteroid implants and Intravitreal triamcinolone acetonide (IVTA) injection in treatment of noninfectious uveitic macular edema. [32] Every BRVO-affected eye was treated with monthly intravitreal ranibizumab injection. [33]유리체강내 라니비주맙 주사 3회 후 광간섭단층촬영-혈관조영술에서 신생혈관이 퇴행하고 시력이 호전되었다. [1] 이 증례보고는 망막하 신생혈관막 증례를 유리체강내 라니비주맙 주사로 관리한 방법을 기술하고 있다. [2] 6안은 이전에 다이오드 레이저 광응고술을 받았고 1안은 유리체강내 라니비주맙 주사를 맞았습니다. [3] 이 연구는 유리체강내 라니비주맙 주사(IVR) 후 중심 망막 정맥 폐쇄(CRVO) 환자의 입체시 및 시력 관련 삶의 질(VR-QOL) 변화를 평가하고 입체시와 VR-QOL 간의 관계를 조사하는 것을 목표로 했습니다. [4] 이 연구는 당뇨병성 황반부종(DME) 환자에서 유리체강내 라니비주맙 주사(IRI) 후 8가지 성장인자와 염증 매개체의 방수 수치 변화와 이들 물질과 기능적-형태학적 매개변수 사이의 관계를 조사하는 것을 목적으로 합니다. [5] 목적: 결합된 망막상막(ERM)이 있는 CRVO 환자에서 유리체강내 라니비주맙 주사로 내부 제한막(ILM) 박리를 사용한 유리체 절제술의 역할을 평가합니다. [6] 현재 발표 전에 그녀는 유리체강내 라니비주맙 주사 3회와 유리체강내 애플리버셉트 주사 9회를 받았습니다. [7] 망막 분지 정맥 폐색(BRVO) 환자에서 유리체강내 라니비주맙 주사(IVR)가 변태에 미치는 영향을 평가하고 변태와 망막 내부 미세구조 및 기타 요인 간의 관계를 평가합니다. [8] 그녀는 단일 유리체내 라니비주맙 주사로 치료를 받았습니다. [9] 행동 양식 이 후향적 연구는 이전에 4~8주 간격으로 라니비주맙을 6회 이상 유리체강내 주사한 후 애플리버셉트로 전환한 신생혈관 연령 관련 황반변성 환자를 조사했습니다. [10] 목적 실제 임상 환경에서 당뇨병성 황반 부종에 대해 유리체강내 라니비주맙 주사를 받는 환자의 주사 패턴 및 시력 결과를 평가합니다. [11] nan [12] nan [13] 33안은 유리체강내 애플리버셉트 주사를, 21안은 유리체강내 라니비주맙 주사를 시행하였다. [14] 유리체강내 라니비주맙 주사는 4주 간격으로 3회 투여되었습니다. [15] 모든 눈은 절제 요법과 결합된 유리체강내 라니비주맙 주사를 받았습니다. 14(87. [16] 3%) 유리체강내 라니비주맙 주사(IVR)를 받았고; 및 유아 2명(4안, 0. [17] 유리체내 애플리버셉트는 망막 광응고술, 안구주위 트리암시놀론 및 유리체내 라니비주맙 주사 후 지속적인 망막 신생혈관이 발생한 후 구조 요법으로 투여되었다. [18] 양안의 유리체강내 라니비주맙 주사 후 해부학적 개선은 유의했지만 일시적이었습니다. [19] 항녹내장 약물, 유리체강내 라니비주맙 주사 및 국소 방사선 요법은 그녀의 안압(IOP) 및 안구 통증을 감소시키는 데 효과가 없었습니다. [20] nan [21] nan [22] nan [23] nan [24] nan [25] nan [26] nan [27] nan [28] nan [29] nan [30] nan [31] nan [32] nan [33]
intravitreal ranibizumab treatment 유리체강내 라니비주맙 치료
Conclusions Intravitreal ranibizumab treatment resulted in improvement in visual acuity, anatomical change, and visual function change in Japanese AMD patients. [1] Results During the study period, Clalit affiliated ophthalmologists’ submitted 16,778 funding applications for intravitreal ranibizumab treatment on behalf of 5642 patients who applied for approximately three applications. [2] The treatment-naïve diabetic macular edema patients who had diabetic macular edema associated with subfoveal retinal detachment and underwent intravitreal aflibercept or intravitreal ranibizumab treatment were included. [3] Purpose: To investigate vision-related quality of life in patients referred to the Italian Retina Services for intravitreal ranibizumab treatment for choroidal neovascularization due to pathologic myopia. [4] Purpose To compare prospectively intravitreal ranibizumab treatment and pars plana vitrectomy (PPV) in patients with recurrent vitreous haemorrhage (VH) due to proliferative diabetic retinopathy (PDR), who were previously treated with PPV. [5] Conclusions: SD-OCT-guided intravitreal ranibizumab treatment in mCNV was efficient and safe. [6] ABSTRACT Purpose: To study (i) the long-term effects of intravitreal ranibizumab treatment on changes in submacular choroidal thickness and (ii) the relationship between any resulting changes in choroidal thickness and visual outcomes following such treatment in patients with neovascular age-related macular degeneration (n-AMD). [7] gov: NCT02810808), patients were randomized (1 : 1) to 1 dose + PRN (PRN group) or 3 loading doses + PRN (LD group) using intravitreal ranibizumab treatment. [8]결론 유리체강내 라니비주맙 치료는 일본 AMD 환자에서 시력, 해부학적 변화 및 시각 기능 변화의 개선을 가져왔습니다. [1] 결과 연구 기간 동안 Clalit 계열 안과 의사들은 약 3건의 신청서를 신청한 5642명의 환자를 대신하여 유리체강내 라니비주맙 치료에 대한 16,778건의 자금 지원 신청서를 제출했습니다. [2] nan [3] nan [4] nan [5] nan [6] nan [7] nan [8]
intravitreal ranibizumab therapy
Design, Setting, and Participants This economic evaluation predominantly used data from the Center for Value-Based Medicine database to perform preference-based comparative effectiveness and cost-utility analyses for cataract surgery and intravitreal ranibizumab therapy for neovascular age-related macular degeneration (NVAMD) using vision utilities acquired from patients with ophthalmic disease (ophthalmic patient utilities) and from surrogate individuals (nonophthalmic patient vision utilities) with and without integrating systemic comorbidity utility limits on vision utility gain. [1] Objective: To identify features in enhanced depth imaging spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), and fundus auto fluorescence (FAF) of patients with neovascular age-related macular degeneration (nAMD), as image markers of poor response to intravitreal Ranibizumab therapy. [2] BackgroundThe association of HTRA1 rs11200638 and ARMS2 rs10490924 gene polymorphisms with response to intravitreal ranibizumab therapy among neovascular AMD (nAMD) subjects in Malaysia was determined in this study, followed by the expression of HTRA1 and ARMS2 genes. [3]디자인, 설정 및 참가자 이 경제성 평가는 주로 가치 기반 의학 센터 데이터베이스의 데이터를 사용하여 환자로부터 얻은 시력 유틸리티를 사용하여 신생혈관성 연령 관련 황반변성(NVAMD)에 대한 백내장 수술 및 유리체강내 라니비주맙 치료에 대한 선호도 기반 비교 효과 및 비용 활용 분석을 수행했습니다. 안과 질환이 있는 경우(안과 환자 유틸리티) 및 대리 개인(비안과 환자의 시력 유틸리티)에서 전신 동반이환 유틸리티를 통합하거나 통합하지 않은 경우 시력 효용 이득에 대한 제한이 있습니다. [1] nan [2] nan [3]
intravitreal ranibizumab compared
We evaluated the efficacy and safety of intravitreal ranibizumab compared with laser therapy in treatment of ROP. [1] IntroductionThis study sought to determine the cost-effectiveness of intravitreal ranibizumab compared with best supportive care (BSC; considered to be no active treatment) for the treatment of visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular degeneration (nAMD) and pathologic myopia (PM) in a UK setting. [2]intravitreal ranibizumab biosimilar 유리체강내 라니비주맙 바이오시밀러
Purpose: The aim of this study was to evaluate the safety, efficacy, and morphological response of intravitreal ranibizumab biosimilar (Razumab) in neovascular age-related macular degeneration (n-AMD) up to 12 weeks. [1] To assess the safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab® (Intas Pharmaceuticals, Ahmedabad, India) in chorioretinal disorders under real-world conditions. [2]목적: 이 연구의 목적은 최대 12주까지의 신생혈관 연령 관련 황반변성(n-AMD)에서 유리체강내 라니비주맙 바이오시밀러(Razumab)의 안전성, 유효성 및 형태학적 반응을 평가하는 것이었습니다. [1] 유리체내 라니비주맙 바이오시밀러 분자인 Razumab®(Intas Pharmaceuticals, Ahmedabad, India)의 실제 상황에서 맥락망막 장애에 대한 안전성 프로파일을 평가하기 위해. [2]